Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2007 Oct 15.
Published in final edited form as: Dev Biol. 2007 May 3;307(2):340–355. doi: 10.1016/j.ydbio.2007.04.041

Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer

Andrew Lindsley 1, Paige Snider 1, Hongming Zhou 1, Rhonda Rogers 1, Jian Wang 1, Michael Olaopa 1, Agnieszka Kruzynska-Frejtag 2, Shrinagesh V Koushik 3,5, Brenda Lilly 3, John BE Burch 4, Anthony B Firulli 1, Simon J Conway 1,*
PMCID: PMC1995123  NIHMSID: NIHMS27419  PMID: 17540359

Abstract

Periostin is a fasciclin-containing adhesive glycoprotein that facilitates the migration and differentiation of cells that have undergone epithelial-mesenchymal transformation during embryogenesis and in pathological conditions. Despite the importance of post-transformational differentiation as a general developmental mechanism, little is known how periostin’s embryonic expression is regulated. To help resolve this deficiency, a 3.9kb periostin proximal promoter was isolated and shown to drive tissue-specific expression in the neural crest-derived Schwann cell lineage and in a sub-population of periostin-expressing cells in the cardiac outflow tract endocardial cushions. In order to identify the enhancer and associated DNA binding factor(s) responsible, in vitro promoter dissection was undertaken in a Schwannoma line. Ultimately a 304bpperi enhancer was identified and shown to be capable of recapitulating 3.9kbperi-lacZ in vivo spatiotemporal patterns. Further mutational and EMSA analysis helped identify a minimal 37bp region that is bound by the YY1 transcription factor. The 37bp enhancer was subsequently shown to be essential for in vivo 3.9kbperi-lacZ promoter activity. Taken together, these studies identify an evolutionary-conserved YY1-binding 37bp region within a 304bp periostin core enhancer that is capable of regulating simultaneous novel tissue-specific periostin expression in the cardiac outflow-tract cushion mesenchyme and Schwann cell lineages.

Keywords: periostin, mouse embryo, Schwann cells, heart development, endocardial cushions, peripheral nervous system, lineage restricted promoter, lacZ reporter mice

Introduction

Periostin was originally isolated as osteoblast-specific factor-2 from the mouse osteoblastic cell line MC3T3-E1 (Takeshita et al., 1993). There are five human periostin isoforms, with variations occurring in the C-terminal domain constituting in-frame deletions or insertions, implying alternative splicing events (Litvin et al., 2004). The gene is structurally similar to Fasciclin-I, a Drosophila protein expressed in the peripheral nervous system (PNS) and specific central nervous system axonal bundles (McAllister et al., 1992). Fasciclin-I functions in guidance of migrating cells, cell sorting and adhesion during insect nervous system morphogenesis (Takeshita et al., 1993). The fasciclin extracellular domain is repeated four times in periostin and is evolutionary conserved from man to bacteria (Kawamoto et al., 1998). There are thought to be both membrane-associated forms and secreted forms (Litvin et al., 2005; Kudo et al., 2006). Interestingly, periostin can support osteoblast attachment and spreading. Moreover, periostin may be a ligand for αvβ3 and αvβ5 integrins and promote integrin-dependent cell adhesion and enhance cell motility (Gillian et al., 2002). Recently, periostin has been shown to preferentially localize in collagen rich tissues and can directly interact with collagen Type-I fibrils (Norris et al. 2007). Periostin is widely expressed in normal embryonic/adult tissues and is highly expressed in diverse pathological conditions. Multiple reports have demonstrated elevated serum levels in tumor samples from neuroblastoma (Sasaki et al., 2002), elevated expression in head/neck carcinoma samples (Kudo et al., 2006; Gonzalez et al., 2003), as a novel component of subepithelial fibrosis in bronchial asthma (Takayama et al., 2006), in response to vascular injury (Li et al., 2005), in epithelial ovarian cancer (Gillian et al., 2002) and in patients with bone metastases from breast cancer (Sasaki et al., 2004) that had undergone epithelial-mesenchymal transformation (EMT) and metastasized. Significantly, periostin has been shown to potently promote post-EMT metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway (Bao et al., 2004). It is also thought to be responsible for extracellular matrix (ECM) deposition following myocardial infarction and pathological transformation (Stanton et al., 2000). In normal tissues, periostin is expressed during recruitment and attachment of osteoblast precursors in the fibrous periosteum (Horiuchi et al., 1999; Oshima et al., 2002: Litvin et al., 2004), post-EMT valve formation and remodeling (Kruzynska-Frejtag et al., 2001; Lindsley et al., 2005; Litvin et al., 2005), cranial suture maturation (Oshima et al., 2002), and during epithelial-mesenchymal signaling associated with craniofacial development (Kruzynska-Frejtag et al., 2004). We demonstrated via targeted deletion that periostin (perilacZ) null mice are predominantly viable and exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype (Rios et al., 2005). Similarly, Kii et al. showed that periostin is required for eruption of incisors in mice (Kii et al., 2006). Combined, these mouse knockout data suggest that periostin may be required in utero for events that manifest themselves in postnatal life (Rios et al., 2005).

Despite the complex and intriguing correlation of disregulated periostin expression levels in both normal and pathological transformation conditions, very little is known about how periostin is transcriptionally controlled. Thus, unraveling the molecular mechanisms that regulate periostin expression could prove useful for gaining an understanding of numerous neoplastic diseases as well as normal bone, craniofacial and heart homeostasis. During osteoblast differentiation, transcription of periostin may be regulated by the bHLH transcription factor, Twist (Oshima et al., 2002) that is associated with EMT during tumor progression (Yang et al., 2004). To begin to clarify the molecular regulation of periostin gene expression, we used bioinformatics and cross-species comparisons to identify seven highly-conserved regions within the proximal 3900 base pairs of the periostin promoter. We subsequently cloned the 5′ mouse 3.9kb periostin promoter and in vivo transgenic reporter analysis revealed lineage-restricted in utero expression within only Schwann cells and in a subpopulation of endogenous periostin-expressing cardiac outflow tract (OFT) endocardial cushion cells. Using EMSA and serial truncation/internal deletion luciferase reporter in vitro assays, we demonstrate that a 37bp enhancer is necessary and that the ubiquitous Ying Yang-1 (YY1) zinc finger transcription factor binds this 37bp enhancer within a protein complex. In addition to YY1’s role as an initiator of tumorigenesis and inhibitor of important cell-cycle progression and tumor suppressor genes, there is mounting evidence that YY1 may also play a regulatory role in normal biological processes (Gronroos et al., 2004; Gordon et al., 2005; Wang et al., 2006). Further in vitro site-directed mutagenesis and in vivo deletion assays revealed that this 37bp enhancer is necessary for in vivo Schwann and OFT endocardial cushion lineage reporter expression.

Both Schwann cell and OFT endocardial cushion morphogenesis are dependent upon neural crest morphogenesis (Jessen & Mirsky, 2002; Conway et al., 2000). Most Schwann cells are neural crest-derived (Le Douarin et al., 1991) and undergo a defined series of developmental transitions that ultimately give rise to mature Schwann cells (Jessen & Mirsky, 2005). Following migration of a neural crest subpopulation and subsequent activation of the Schwann cell differentiation cascade, neural crest cells can give rise to Schwann cell precursors that then undergo a series of molecular and morphological changes to generate immature and finally mature myelinating and non-myelinating Schwann cells (Jessen & Mirsky, 2005). Similarly, a subpopulation of the cardiac neural crest lineage migrate and colonize the distal cardiac OFT endocardial cushions, and then undergo a series of molecular and morphological changes that ultimately forms the septa between the aorta and pulmonary artery (Jiang et al., 2000; Conway et al., 2003). These results represent the identification and initial characterization of a novel enhancer element that modulates expression of periostin solely within the post-migratory OFT endocardial cushions and Schwann cell precursors of the developing mouse embryo.

Materials and Methods

Bioinformatics analysis

Paired alignment and visualization of homology between mouse and human PERIOSTIN promoter sequence was undertaken using zPicture software (Ovcharenko et al., 2004; Loots & Ovcharenko, 2004). Multiple alignment of mouse (NC_000069), dog (NC_006607), human (NC_000013), and rat (NC_005101) periostin promoter sequences was accomplished using the ClustalW software (Thompson et al., 1994). Single polymorphic nucleotide analysis of PERIOSTIN upstream sequence revealed the presence of 2 well supported human SNPs (rs17197936a and rs17197908c; indicated in Fig. 6A).

Figure 6. Bioinformatic analysis of conserved sequences.

Figure 6

(A) ClustalW multiple alignment of mouse (−2430 to −2126bps upstream region), rat, dog and human DNA sequences. There are three highly significant evolutionary conserved regions of sufficient size to be potential transcription factor binding sites (highlighted in yellow). Two single-nucleotide polymorphisms (indicated by #) are present in the 304pb enhancer, one is present within the 37bp fragment (blue #). (B) All three sites (designated site1, 2 & 3) were targeted for subsequent site-directed mutagenesis. While mutation of site3 had little effect, mutation of site1 and 2 both significantly reduced luciferase reporter activity in RT4 cells when compared to control 804bpperi enhancer (n=6). Specifically, mutation of site1 reduced luciferase to basal levels (n=6). The less dramatic reduction noted in the mutation of site2 may imply the binding of factors acting synergistically or with factors that also bind site1.

Animal model

Periostin (perilacZ) knockin knockout mice generated previously (Rios et al., 2005) were maintained on a C57BL/6J genetic background and fed powdered Teklad LM-485 Complete Mouse Diet to alleviate runting. Tissue isolation, fixation and processing for lacZ staining was carried out as described (Rios et al., 2005). All animal experimentation was performed in accordance with National Institutes of Health Guidelines, and protocols approved by the Institutional Animal Care and Use Committee at IUPUI (Study #2707).

Generation of 3.9kbperi-lacZ reporter mice

To begin to identify the cis-elements and trans-factors necessary and sufficient for periostin developmental transcriptional activity, we PCR cloned 3.9kb of the 5′ mouse periostin promoter from a 92kb 129SvJ mouse ES cell genomic DNAlibary bacterial artificial chromosome (clone#318a12, Genome System Inc., St. Louis, MO) using a high-fidelity Thermal Ace DNA polymerase kit (Invitrogen, Inc., Carlsbad, CA). Its identity and fidelity were confirmed by 4-fold coverage sequencing and overlaps NCBI Mus musculus chromosome 3 genomic clone #NT_039240. Primers used were as follows: sense (5′ GCgtcgacCTAAGGTGGACAGTGCGGAAGAC-3′) and antisense (CctcgagCTTCAGCCCTGAGCTCCGTCC-3′). The primers were engineered to produce a 5′ SalI site (in lowercase letters) and a 3′ XhoI site (in lowercase letters), which enabled us to directionally clone the insert in frame into a promoterless IRES-nuclear localized β-galactosidase expression cassette. The resulting construct was either introduced as a 3.9kb promoter that contains the 5′-UTR and promoter elements of periostin genomic DNA (upto but not including the ATG) or as a 5′ truncated 1.2kb promoter (following digestion with an internal unique Stu1 site). Following pronuclear injection, resultant embryos were transferred into pseudopregnant C57Bl/6 female oviducts. Resulting F1 mice were screened by Southern blot, and positive males bred to wildtype C57Bl/6 female mice. Two 3.9kbperi-lacZ and four 1.2kbperi-lacZ independent lines were produced, and F2 germline transmission of the transgene was examined by both PCR and lacZ staining (Fig. 2).

Figure 2. The 3.9kbperi-lacZ reporter is expressed in Schwann lineage.

Figure 2

(A) Endogenous periostin protein is expressed in many E14 tissues and organs, particularly in periostium and around dorsal root ganglia (arrow in A). Note that while periostin is expressed in many tissues, it is absent from the neural tube (nt). (B) In newborns, the dorsal root ganglia, its sheath and the nerve emininating from the ganglia are intensely labeled. (C–E) Sections of lacZ stained 3.9kbperi-lacZ transgenic-positive E14 embryo reveals β– galactosidase positive cells throughout dorsal root ganglia (drg) and along nerve tracks (arrow in C). Double-labeling with α–smooth muscle actin (SMA) and neurofilament-H (NF) antibodies, revealed that the lacZ positive cells are neither smooth muscle or nerve cells, as both are mutually exclusively expressed. The 3.9kbperi-lacZ expressing cells appear to surround the nerves, suggesting they are Schwann cells. (F & G) In order to verify that endogenous periostin and the Schwann cell marker Sox10 transcription factor are co-expressed in the dorsal root ganglia, serial sections were probed with 35S-labeled periostin and 35S-labeled Sox10 in situ probes. Whilst Sox10 is restricted to dorsal root ganglia, sympathetic ganglia and the peripheral nerves; periostin is co-expressed with Sox10 in the dorsal root ganglia (arrows in F & G) and is also present within the aortic arch arteries and OFT endocardial cushion cells (oft). (H & I) Identical section of a E14 3.9kbperi-lacZ lacZ-stained embryo was subsequently probed with Sox10 antibody (which marks early Schwann cell precursors). Note co-expression of 3.9kbperi-lacZ reporter and nuclear anti-Sox10 fluorescence (arrows in I).

Histological, in situ and immunohistochemical analysis

Microdissected embryos of various ages were either fixed briefly with 4% paraformaldehyde (PFA), flash frozen directly in OCT mounting media (Sakura Finetek, Torrance, CA) following 10%, 20%, 30% sucrose protection or directly stained for lacZ and examined as described (Rios et al., 2005). At least 5 embryos at each developmental stage were assessed for β-galactosidase reporter activity. Immunodetection of periostin (1:8,000 dilution), α-smooth muscle actin (1:5,000 dilution, αSMA, Sigma, St. Louis MO) and neurofilament-H (1:8,000 dilution, Chemicon) were performed as described (Kruzynska-Frejtag et al., 2004). Unfixed frozen embedded embryos were sectioned (10μm), fixed briefly with 4% PFA, stained for lacZ, and then washed in saline prior to protein blocking and incubation with a goat anti-Sox10 antibody (1:75 dilution, Santa Cruz Biotech, CA) and detection via rabbit anti-goat-FITC secondary antibody (1:100 dilution, Vector Labs, CA). Both sets of immunoassays were repeated at least 3 times.

Radioactive in situ hybridization detection of endogenous periostin expression was performed as previously described (Kruzynska-Frejtag et al., 2001). Sox10 mRNA expression was detected using a cDNA probe, cloned via PCR amplification from E12.5 whole embryo cDNA using the following primers: 5′-TCTGTCTTCACCTGGGCTTT and 3′-ATGTCAGATGGGAACCCAGA. The 420bp Sox10 PCR fragment was cloned into the pCRIITOPO vector (Invitrogen) and sequenced to verify identity and orientation. Both sense and antisense 35S -UTP-labeled probes were generated, and specific signal was only observed when sections were hybridized with the antisense probe (repeated at least 3 times).

RT4-D6P2T cell line

RT4-D6P2T (RT4) rat Schwannoma cells (a kind gift of Dr. Pragna Patel, USC) were grown in DMEM (Gibco), supplemented with 10% fetal bovine serum and 100U/mL penicillin and 100 ug/mL streptomyosin at 37°C with 5% CO2.

In order to characterize the RT4 cells and assess endogenous periostin expression, both RT4 and NIH3T3 (ATCC) lines were used. Additionally, newborn extracts (n=3) from wildtype and perilacZ null mice were used for Western analysis as described (Rios et al., 2005). For analysis, ~100μg of cell lysate and medium (equal amounts for RT4 and NIH3T3), and ~ 80μg newborn samples were resolved via 12% SDS-PAGE (Bio-Rad). Loading was normalized using a monoclonal anti-actin antibody (Sigma) at 1:5,000 dilution and the relative levels of periostin measured using our affinity-purified anti-periostin rabbit polyclonal antibody at 1:12,000 dilution (Kruzynska-Frejtag et al., 2004).

For immunohistochemical analysis, cells were grown on glass culture slides (LabTech, Nalge-Nunc Inc.), fixed briefly with 4% PFA and stained for periostin and Sox10 as described above (n=3). Anti-S100 staining was accomplished using the S-100 Immunohostology Kit (cat. IMMH-9, Sigma-Aldrich, St. Louis, MO). All images were taken using a Zeiss AxioSkop2 Plus.

Luciferase Reporter Constructs, Mutagenesis, Transfection & Luminometry

The 3.9kb proximal periostin promoter was directionally cloned into the promoterless pGL2-Basic vector (Promega Corp., Madison WI). The sequenced 3.9kbperi-pGL2 clone was then serially and internally deleted to generate a set of truncated constructs. In addition, site-directed mutagenesis of three mouse-human homology sites was accomplished using the GeneTailor Site-Directed Mutagenesis System in a pSKII Bluescript shuttle vector (Invitrogen Carlsbad, CA). Following sequencing verification of designed mutations, both a 804bp and internal 304bp enhancer were excised and ligated into pGL2 vectors for reporter analysis.

Molar equivalents of each construct and 50ng of the Renilla control plasmid (pRL-CMV, Promega) were co-transfected into RT4 cells using the Mirus TransIt-LT1 lipoamine reagent (Mirus Bio Corp. Madison, WI). Following 48hrs incubation at 37°C, protein lysates were harvested from transfected cells and accessed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega Corp.) Quantitative luminometry was performed using a Lmax luminometer (Mol. Devices, Sunnyvale, CA). Each transfection was performed three separate times in duplicate and each sample was read twice.

Electromobility Shift Assays (EMSA)

Nuclear extract was isolated from RT4 cells following a modified Dignam protocol (Dignam et al., 1983) and EMSAs performed as described (McFadden et al., 2000). Radioactive double-stranded DNA probes were generated from P32-labeled complimentary single stranded oligos and purified by acrylamide gel purification. Cold probe was generated from the hybridization of unlabeled oligos. The sequences for the probes are listed in table below:

Site 1 5′-ATAATGAACCATTTCTTTCT-3′
Site 2 5′-TCAGTAATGACTTACATCT-3′
Site 3 5′-ACATCTCTGGGTCAGACTTT-3′
Site 12 5′-TAATGAACCATTTCTTTCTCAGTAATGACTTACATCT-3′
Site 123 5′-TAATGAACCATTTCTTTCTCAGTAATGACTTACATCTCT GGGTCAGACTTT-3′
Non-specific 5′-GCTCCACCGCCATCTCCGTATTA-3′
YY1 control 5′-ATGCCTTGCAAAATGGCGTTACTGCAG-3′
SRF control 5′-ACACAGGATGTCCATATTAGGACATCTGC-3′

Pure YY1 protein was generated from both pcDNA3-CMV-YY1 and pcDNA3-CMV-YY1-His tagged full length cDNA vectors using the TnT rabbit reticulocyte lysate expression system (Promega). Equivalent amounts of both YY1 and un-programmed lysate were used in EMSA analysis to assess the ability of YY1 to bind the Site 123 probe listed above. Western blotting with the YY1-specific antibody (1:1,000 dilution; Santa Cruz) was used to verify that only programmed lystate contained YY1.

Generation of Hsp68-804peri-lacZ, Hsp68-304peri-lacZ and Hsp68-3900−37bp transient Fo transgenic analysis

Two DNA fragments, corresponding to −2924 to −2119 (804bp) and −2509 to −2205 (304bp), were isolated, blunted via Klenow and ligated into a minimal promoter-lacZ reporter vector, Hsp68-lacZ (Kothary et al., 1989; McFadden et al., 2000). The 37bp enhancer, corresponding to −2373 to −2336 was deleted from the original 3.9kb 5′-prime UTR and promoter fragment using the GeneTailor Site-Directed Mutagenesis System, to make the Hsp68-3900−37bp mice. F0 transgenic mice were generated by pronuclear injection of the various linearized transgenes (IU School of Medicine Transgenic Core Facility) and harvested at E12-13 gestational age. Following microdissection and isolation of limb buds for PCR genotyping, F0 embryos were fixed, stained for lacZ, and paraffin embedded for detailed histological analysis.

Results

Bioinformatic Analysis

In order to better understand the mechanisms driving dynamic periostin expression in utero, we made use of comparative species sequence analysis. Such analysis is based on the concept that small non-coding sequences conserved between related species are likely the product of positive selection and often contain critical transcriptional regulatory elements. Cross-species comparison indicates that the majority of evolutionarily conserved domains were present within the proximal 4kb of periostin upstream region relative to the location of the transcriptional start site. This putative periostin promoter sequence, designated 3.9kbperi, includes 3866bp of the sequence immediately upstream of the transcriptional start site and 18bps of non-coding exon 1. Comparative analysis reveals relatively homogenous distribution of highly conserved sequence between rat and mouse (86.2% identity). In contrast, when 3.9kbperi was aligned with more distantly related species such as dog and human, seven discrete focal peaks of high identity are revealed (data not shown). Interestingly, the peaks in the two non-rodent species were highly similar, both in term of degree of sequence identity and spatial distribution. As a number of possible cis-modules were identified within the proximal 4kb of periostin, we tested their role directly by generating transgenic mice designed to drive expression of the β-galactosidase reporter via this conserved 3.9kbperi region.

Periostin Proximal 3.9kb Promoter Expression Patterns

The 3.9kbperi sequence was cloned into a nuclear-localized β-galactosidase reporter vector. The resulting construct was either introduced as an intact 3.9kb periostin promoter or as a 5′ truncated 1.2kb periostin promoter (following digestion with a unique internal Stu1 site). The 1.2kb construct facilitated the in vivo assessment of a previously identified in vitro Twist binding site at position −468bp (Oshima et al., 2002).

Two 3.9kbperi-lacZ and four 1.2kbperi-lacZ independent permanent mice lines were produced and their respective β-galactosidase reporter expression patterns examined. Transgenic analysis revealed that the 1.2kbperi-lacZ promoter (all four lines) was not capable of driving any lacZ reporter expression in vivo at any stage during embryonic and extraembryonic development (E8-newborn stages examined; not shown). In contrast, spatiotemporal analysis of two independent 3.9kbperi-lacZ lines revealed that lacZ reporter expression is present throughout the PNS, enteric nervous system and within a subpopulation of cardiac OFT endocardial cushion mesenchymal cells. In contrast to the relatively widespread endogenous periostin embryonic gene expression (Kruzynska-Frejtag et al., 2001; Kruzynska-Frejtag et al., 2004; Lindsley et al., 2005; Rios et al., 2005), 3.9kbperi-lacZ expression is only present in restricted subpopulations. As both 3.9kbperi-lacZ lines exhibited similar reproducible expression patterns and were both found in normal Mendelian ratios, subsequent analysis and data are derived from line #1 to ensure consistency.

Reporter 3.9kbperi-lacZ expression is initially detected at E10 within the post-migratory pre-Schwann cell precursors. This makes the 3.9kbperi enhancer one of the earliest developmentally-regulated Schwann cell promoters to date. The 3.9kbperi-lacZ expressing cells radiate out from the presumptive dorsal root ganglia and encapsulate the developing peripheral nerves (Fig. 1), including the enteric nerves of the developing gut, establishing the periostin promoter as a novel Schwann cell in vivo marker (Fig. 1). Robust reporter expression in the Schwann cells is maintained throughout embryogenesis, perinatal development and into adulthood (Fig. 1), indicating that both periostin and 3.9kbperi enhancer expression are maintained during transition of the neural crest-derived precursor into mature Schwann cells. The validity of the reporter expression as well as the identity of the stained cells was established by marker gene analysis and co-localization of 3.9kbperi-lacZ expression with the Schwann cell marker Sox10 transcription factor (Fig. 2) (Britsch et al., 2001). Thus, the 3.9kbperi-lacZ promoter is unable to completely recapitulate endogenous periostin expression (Fig. 2), but is capable of driving reporter expression within a subpopulation of endogenously expressing periostin cells. This is consistent with the hypothesis that modular cis elements coordinately regulate complex gene expression patterns (Firulli & Olson, 1997).

Figure 1. Developmental expression pattern of 3.9kbperi-lacZ transgenic reporter.

Figure 1

Developmental series of mouse embryos E10-18 and adult organs stained to detect 3.9kbperi-lacZ-expressing β-galactosidase-positive cells using X-gal substrate (n=48). (A) Note expression begins at ~E10 in the trunk PNS adjacent to the forelimb (arrow in A) and continues throughout development as the staining intensity progressively increases (B–H). Weak 3.9kbperi-lacZ expression can initially be detected in E11 facial ganglia and facial nerves (C). Robust punctuate 3.9kbperi-lacZ expression is also present in E15 midgut enteric nervous system (arrow in H) and fetal dorsal root ganglia and corresponding nerves (arrows in I). Note that 3.9kbperi-lacZ expression is absent from the CNS. Postnatally, 3.9kbperi-lacZ expression is maintained in the left and right sympathetic trunks and ganglia (arrows in J), and in the network of adult enteric ganglia (K).

In addition to Schwann cell expression, mesenchymal cells of the cardiac OFT cushions also exhibit 3.9kbperi-lacZ expression. At E10, a few individual lacZ-positive cells can be detected in the truncal region of the OFT (Fig. 3). Coincident with initiation of mesenchymal condensation and OFT septation, additional lacZ-positive cells are seen at E11 and by E12 two robust streams of 3.9kbperi-lacZ expressing cells can be observed in the aortic and pulmonary conotruncal endocardial cushions. By E14, these streams have resolved into a small clump of lacZ-positive cells at the base of the OFT. Significantly, lacZ staining revealed that the 3.9kbperi-lacZ expression in the OFT is uniquely restricted (Fig. 3). While knockin perilacZ, periostin mRNA and protein are all detected throughout both the proximal and distal OFT and atrioventricular (AV) cushions, 3.9kbperi-lacZ reporter expression is restricted to a subpopulation of distal OFT endocardial cushion cells. This indicates that elements required for AV cushion expression are absent from the 3.9kb promoter and may lie outside the 3.9kb domain. Together these data indicate that a subset of cis-regulatory elements reside within the proximal 4kb of mouse periostin and that these elements drive expression in Schwann cells and the cardiac OFT. To further refine the location of these cis-elements we initiated in vitro analysis using a Schwannoma cell line.

Figure 3. 3.9kbperi-lacZ reporter is also expressed in the developing heart.

Figure 3

Developmental series of 3.9kbperi-lacZ mouse embryo hearts (A–F) and a heterozygous knockin perilacZ heart (G & H). Isolated lacZ-stained 3.9kbperi-lacZ whole hearts at E10 (A), E11 (B), E12 (C) and E14 (D). Black arrows indicate location of 3.9kbperi-lacZ expressing cells. Note speckled expression begins at ~E10.0 within the OFT, and expression increases as development proceeds. (C) Two robust streams of lacZ positive cells are restricted to the truncal region of the E12 OFT endocardial cushions (indicated by arrows). Also note the 3.9kbperi-lacZ reporter is restricted to the OFT and not present in AV region (inset in C in rear view of heart shown in C). (D) The two lacZ-positive streams resolve into a single clump at the base of the E14 OFT, coincident with completion of OFT septation and interventricular septal closure. (E & F) Eosin counter-staining of sections through the truncal and AV regions of the 3.9kbperi-lacZ heart shown in C. Note that 3.9kbperi lacZ-positive cells are present in the mesenchymalizing OFT cushion septum (E), but are absent from the surrounding myocardial cuff and overlying endothelial cells. (F) No 3.9kbperi-lacZ lacZ expression is detectable in AV cushions (indicated by arrow). (G & H) Wholemount E12 heterozygous knockin perilacZ hearts stained for lacZ reveal that endogenous periostin lacZ reporter is robustly expressed in both the OFT (large arrow in G, heart viewed from front) and the AV endocardial cushions (large arrow in H, heart viewed from back). Abbreviations: RV=right ventricle; LV=left ventricle; Ao=aortic orifice; P=pulmonary orifice.

RT4-D6P2T Schwannoma Cell Line Characterization

While transgenic analysis is unrivaled in its ability to characterize promoter activity in all of the tissues of a developing embryo, the technique is not practical for the systematic identification of smaller regulator modules within a putative promoter. In contrast, cell culture-based methods have been highly successful alternatives to exhaustive and expensive in vivo transgenic analysis. Unfortunately, cell culture approaches require the availability of cell lines ontologically appropriate for the expression pattern of the gene of interest. Given the correlation of aberrant periostin expression in multiple neoplasias and the robust and sustained 3.9kbperi-lacZ reporter expression in the PNS, plus the current lack of availability of any suitable endocardial cushion cell line, we used the well characterized RT4-D6P2T (RT4) rat Schwannoma cell line (Toda et al., 1994; Hai et al., 2002). Schwannomas are benign nerve sheath tumors composed of abnormally proliferating Schwann cells. RT4 cells have successfully been used for the molecular analyses of myelin and other PNS-specific promoters (Madison et al., 1996; Gonzalez-Martinez et al., 2003). Prior to molecular dissection of the 3.9kb periostin promoter and to verify whether the RT4 cells would be useful within our system, marker analysis was performed and periostin expression examined. Western blotting reveals that RT4 cells normally express periostin and moreover they express both ECM-bound and secreted isoforms, analogous to those expressed by mouse in vivo (Fig. 4A). The cell line also proved to be immuno-positive for S-100, a cytoplasmic EF-hand calcium binding protein (Jessen & Mirsky, 2002) found predominately in Schwann cells and other glial elements (Fig. 4B). Immunofluorescent detection of the HMG-containing transcription factor Sox10, a Schwann cell marker (Ye et al., 1996; Kuhlbrodt et al., 1998; Britsch et al., 2001), revealed a strong, nuclear localized signal in RT4 cells (Fig. 4C). Finally, the RT4 cell line is also positive for periostin protein within the cytoplasm, thus confirming that our gene of interest was actively expressed by our in vitro model system, and therefore appropriate for promoter analysis (Fig. 4D).

Figure 4. RT4-D6P2T characterization.

Figure 4

(A) Western analysis revealed the RT4 Schwannoma cell line, as opposed to NIH3T3 fibroblast line, expresses the higher molecular weight secreted periostin isoform, similar to the multiple isoforms expressed endogenously in vivo in newborn mice pups. While RT4 cells predominantly express two isoforms (~90kDa & ~82kDa) and RT4 supernanatant contains secreted (~90kDa) periostin, the NIH3T3 cells only express the lower molecular weight (~82kDa) isoform within the cells and do not secrete periostin. Note that there is also a complete absence of periostin in the newborn nulls, verifying antibody specificity. Equal loading was ensured via normalizing for actin levels and loading equivalent amounts of supernatant (verified via Coomassie blue staining, not shown). (B–D) RT4 cells were grown on uncoated glass culture slides and briefly fixed with 4% PFA prior to immunostaining. (B) Anti S-100 staining, with hematoxylin nuclear counterstaining. Note cytoplasmic S-100 expression and absence of specific signal in negative control which did not receive the primary antibody (inset in B). (C) Anti-Sox10 immunofluorescent staining. Note appropriately localized Sox10 expression in nucleus and same view as phase-contrast (inset in C). (D) Anti-periostin staining, with methyl green nuclear counterstain and DIC optics. Note expression of periostin localized to the cytoplasm and that no expression is evident in negative control stained with pre-immune in place of primary periostin antibody (inset in D). The absence of staining in negative (−ve) control samples demonstrated that staining was specific. Magnification: all images 400X.

3.9kbperi Deletion Analysis

To facilitate the identification of specific regulatory elements, we cloned the 3.9kbperi enhancer into the promoterless pGL2-Basic firefly luciferase construct. Serially truncated and internally deleted daughter constructs were all derived from the pGL2-3.9kbperi plasmid (Fig. 5). Transfection efficiency was controlled for by cotransfection of a Renilla luciferase expression plasmid.

Figure 5. In vitro analysis of 3.9kbperi enhancer.

Figure 5

(A) Serial and internal truncation of 3.9kbperi-pGL2 construct and luminometry results. Schematic of constructs are shown with nucleotide assignment given relative to the transcriptional start site (+1). Sequence includes 18bp of exon one, up to, but not including the ATG translational start site. (α, alpha) Corresponds to an 804bp putative enhancer region from −2924 to −2119bps upstream of the transcriptional start. (β, beta) Corresponds to a 477bp putative repressor region from −1287 to −810bps upstream of the transcriptional start. (B) Dissection of 803bpperi putative enhancer region. Schematic alignment of the sequences of truncated enhancer-minimal promoter fusion constructs and intact 3.9kbperi-pGL2 plasmid. Black bars represent the average of six independent transfections (n=6), while error bars represent the standard error. Lysates from each transfection were read twice and the results averaged. Luminometry results are given in arbitrary units.

The resulting luciferase reporter data revealed both activating (α, alpha) and repressing (β, beta) elements within the periostin proximal promoter (Fig. 5A). Construct A contains the 3.9kbperi sequence. When compared to cells transfected with the promoterless pGL2 parent vector, construct A generates a luciferase activity ~500-fold stronger, indicating the presence of the periostin transcriptional start site and putative cis-elements (data not shown). Deletion of 942bp from the 5′ prime end (construct B) results in a 35.3% drop in luciferase activity, while a more significant 77.7% drop was observed when an additional 498bp were removed (construct C). Additional truncation (constructs D–G) did little to further reduced luciferase reporter activity, suggesting that the reporter activity represents the baseline level of transcription from the periostin promoter. Deletion of the putative TATA box further reduced levels of expression comparable to that observed with pGL2-Basic vector only, supporting this conclusion (data not shown). Serial deletion analysis therefore suggested that the most potent transcriptional activation domains were contained in the most 5′ prime 1.4kb of the 3.9kbperi sequences, consistent with our 3.9kbperi (Fig. 1) and 1.2kbperi in vivo transgenic data.

We next engineered additional constructs with internal deletions and assessed resultant reporter activity (constructs H–J). To further characterize the 5′ prime 1.4kb element(s) we first removed an internal DNA fragment from −2119 to −1287. This construct (construct H) shows an increased luciferase activity of ~80% compared to the activity of 3.9kbperi (construct A) suggesting the presence of a possible transcriptional repressor element. A similar level of transcriptional activity was observed when construct H was further truncated by the removal of its distal 942bps (construct J), however, removal of a larger 1637bp internal fragment (construct I) reduced luciferase activity to the levels observed with construct G. These results suggest the existence of a transcriptional enhancer within the 804bp segment of DNA spanning −2924 to −2119 region. A 477bp internal deletion (construct K), was also found to significantly increase luciferase activity from that observed with construct A, suggesting that these sequences may contribute to the negative regulation of periostin.

In order to further define the putative cis-element, we designed a set of constructs that isolated the enhancing 804bp fragment from other regulatory elements within the full length 3.9kbperi while preserving the DNA elements need to drive the basal transcription. This strategy utilized the minimal promoter region corresponding to the 423bps immediately upstream of the transcriptional start site. The putative 804bp enhancer element was fused to the 5′ end of the minimal promoter element and its transcriptional activity assessed (Fig. 5, construct iii). An 18.8-fold increase in luciferase reporter activity is observed. Subsequent truncation of the 804bp fragment (constructs iv-vii) results in decreased luciferase activity. Nevertheless, a moderately enhancing 304bp core fragment (−2509 to −2205) was identified within the larger 804bp fragment, that was sufficient to drive luciferase expression at a level equivalent to that observed for 3.9kbperi promoter. Significantly, sequence identity bioinformatics of the 3.9kbperi promoter revealed that this 304bp (−2509 to −2205) fragment is localized within the region that contains the highest level of evolutionary conservation (72.94%). Table 1 is a bioinformatics representation of all known and conserved cis-elements within the 304bpperi minimal enhancer. To further refine our analysis of these regions, we carefully examined conserved and aligned sequences within the 304bp fragment. Three highly conserved putative transcription factor-binding sites (highlighted in yellow) were identified and targeted for additional analysis (Fig. 6A).

Table 1. Bioinformatics representation of known and conserved cis-elements within the 304bp minimal enhancer.

Cis-element scan analysis was performed using the MatInspector program, (Genomatix http://www.genomatix.de/) on the 304bpperi enhancer contained within −2509 to −2205bps of 3.9kbperi promoter (note necessary 37bp fragment is underlined and YY1 elements are indicated via enlarged text). The Optimized matrix threshold was set to minimize false positive hits, and only the highest conserved consensus binding sites (each >0.8) are indicated (note: a perfect match to the matrix scores 1.00, while strong candidates typically show a similarity of >0.80). The sequence that corresponds to each of the identified cis-elements are denoted on 304bpperi enhancer via the color-coded key. An “r” superscript indicates that the element is in reverse orientation in relation to the start site. Potential interesting elements identified include several Gata sites and retinoic acid response elements, an Oct consensus site and pancreatic/intestinal Lim-homeodomain factor (Isl1) and activator protein-1 (AP-1) sites found within the 37bp fragment. Ap-1 has been shown to play a critical role in Schwann cells differentiation (Miskimins & Miskimins, 2001; Wegner, 2000) and the myocardialized OFT septum has recently been shown to be derived from Isl1 expressing cells (Sun et al., 2006).

graphic file with name nihms27419f10.jpg

Enhancer Mutagenesis

Using site-directed mutagenesis, we fused the 804bp enhancer to the periostin minimal promoter (construct iii) and then disrupted the three most highly conserved modules identified by bioinformatic analysis (Fig. 6B). Mutation of site 1 and site 2 reduced luciferase activity by ~80% and ~65%, respectively, while mutation of site 3 had a minimal effect (~17% reduction). Mutation of site 1 reduced luciferase activity nearly to basal levels, implying that a necessary trans-activator(s) requires the cis-elements of site 1’s sequence in order to bind and drive transcription. The less dramatic reduction observed via mutation of site 2 may imply the binding of factors which moderately enhance periostin’s transcription. Although these data suggest we have further isolated the cis-elements within the 3.9kbperi promoter, validation was required to be sure that these elements function in vivo.

Transient F0 Transgenic Analysis

Given the predictions provided by the in vitro analysis of the promoter, we sought to validate our findings in vivo. Both the 804bp and 304bp putative enhancer elements were cloned into an Hsp68-lacZ minimal promoter construct and were used to generate F0 transgenic embryos. At E12.5 (stage at which 3.9kbperi reporter expression is maximal in PNS and OFT), both the Hsp68-804bpperi-lacZ (n=11) and the Hsp68-304bpperi-lacZ (n=6) positive embryos yielded Schwann cell expression throughout the developing PNS (Fig. 7). Intriguingly, both constructs yielded embryos that were uniformly lacZ positive in the mesenchymal cells of the distal OFT cardiac cushion while only individual, isolated lacZ positive cells were observed to sparsely populate the AV cushion (Fig. 7B). Histological analysis revealed that lacZ expression was restricted to the mesenchyme of the distal OFT cushion, while the overlying endocardium and surrounding myocardium were negative (Fig. 7B,C). When compared to the 3.9kbperi-lacZ expression pattern (see Fig. 3), the expression patterns of Hsp68-804bpperi-lacZ and the Hsp68-304bpperi-lacZ are both more extensive in the cardiac cushions, however, they are not ectopic in nature. As endogenous periostin mRNA and protein expression can be found throughout the proximal and distal OFT and AV cushion mesenchyme (Kruzynska-Frejtag et al., 2001; Lindsley et al., 2005; Litvin et al., 2005), this suggests that different enhancers may regulate endocardial cushion periostin expression in different cushions and within different regions of each cushion. Given the probable repressive element within the proximal region of 3.9kbperi, the less restricted expression patterns of Hsp68-804bpperi-lacZ and Hsp68-304bpperi-lacZ may be secondary to the removal of a negative putative regulatory element.

Figure 7. Transgenic Fo analysis of periostin enhancer expression.

Figure 7

(A) E12.5 whole embryos and isolated hearts stained for lacZ reporter activity. First three panels illustrate F0 transient transgenic pattern driven by 804bpperi enhancer (n=11), while nextthree panels illustrate F0 304bpperi enhancer expression (n=6). Note that the 804bpperi-lacZ enhancer recapitulates 3.9kbperi-lacZ PNS (indicated by *) and OFT reporter patterns, and in fact 804bpperi-lacZ OFT levels may even be enhanced as lacZ expression is now present within the most of the truncal and conal endocardial cushion cells. However, 304bpperi-lacZ PNS lacZ expression is markedly reduced (indicated by *) whilst OFT expression is still robust, although restricted to the truncal region. (B) Histological sectioning reveals that 804bpperi-lacZ reporter expression is confined to the endocardial cushions within the OFT (arrow). Note that some AV cushion expression is now evident, suggesting loss of repression. (C) Histological sectioning reveals that 304bpperi-lacZ expression is also restricted to endocardial cushion cells but is absent in the adjacent myocardial cuff and endothelial cells. Note 304bpperi-lacZ expression is present in truncal cushions (large arrow in C) but is absent in the conal region (small arrow in C).

Protein–DNA Interaction Analysis

To assess the protein binding capacity of the identified periostin enhancers, 20bp 32P-radiolabeled double-stranded DNA probes where generated for sites 1–3 and Electromobility Shift Assays (EMSAs) were performed. Each probe contained a single identified site and a minimum of 5bp of upstream and downstream flanking sequence. Surprisingly, incubation with RT4 nuclear extract failed to retard the migration of any of the individual 20bp probes (Fig. 8B). In contrast, when a probe encompassing all three sites (52bp in total length) was incubated with the same RT4 nuclear extract, two prominent shifted bands (complex A, B) and one faint higher shifted band (complex C) were detected (Fig. 8C). The use of unlabeled “cold” probe successfully reduced the intensity of all three bands in a dose-proportionate manner whereas a non-specific DNA sequence of similar length has no such effect. Given that mutation of site 3 had little effect on promoter luciferase activity (Fig. 6B), we designed a probe 37bp in length to examine the protein-binding capacity of just sites 1 and 2 (Fig. 8D). Results demonstrate that both the 52bp (sites 1,2&3) and 37bp (sites 1&2) EMSA probes are specifically-bound by RT4 nuclear extract proteins (whereas single site 20bp probes did not) and that they yield a similar distribution of three DNA-protein complexes, each with discrete migratory properties.

Figure 8. Biochemical analysis of 304bpperi enhancer.

Figure 8

(A) Annotated schematic illustrating alignment of various EMSA oligonucleotide probes containing conserved sites 1, 2 and 3 (highlighted in yellow). Oligo123 is a 52bp probe containing all three sites of homology. Aligned below are the sequences of Oligo1, Oligo2, and Oligo3, each represents a 20bp probe centered on a specific site of homology. Oligo12 is a 37bp probe containing just sites 1 and 2. Putative YY1 transcription factor binding sites are aligned below to reveal their inclusion or exclusion within the various probes. (B) 32P-labeled 20bp double-stranded DNA probes as described above were hybridized with 3μg of RT4 derived nuclear extract and cold probe. Note the absence of any bands for all three 20bp probes, indicating that none of the probes alone is sufficient to generate DNA-protein complexes. (C) In contrast, when 32P-labeled Oligo123 is co-incubated with the identical nuclear extract, 2 prominent bands and 1 faint band are generated (denoted as complexes A, B, C). Note that there is a dose-dependent competition of bands with unlabeled cold probe. (D) EMSA analysis of 37bp fragment. 32P-radiolabeled 37bp probe was generated equivalent to Oligo12. Incubation with RT4 nuclear extract resulted in one prominent shifted band and two faint higher shifted bands (arrowheads, denoted as complexes A, B & C). Note that competition with specific cold competitor abolished all bands, while non-specific cognate probe had negligible effects. Significantly, given the presence of a YY1 binding site, cold YY1 probe greatly diminished bands whilst cold SRF probe had minimal effect. Site-directed mutation of either site1 or site2 resulted in alerted stochiometry/intensity of the bands, but did not abolish presence of any shifted bands (complexes A*, B* & C*). (E) EMSA analysis of 37bp fragment with YY1-programmed extracts. Pure YY1 protein was generated from pcDNA3-CMV-YY1 full length cDNA vector using TnT rabbit reticulocyte lysate expression system (Promega). Un-programmed lystate failed to retard the migration of the 37bp probe, whilst both His-tagged YY1 (slightly larger due to his tag) and YY1 alone resulted in shifted bands. Western blotting with YY1-speific antibody was used to verify that only the programmed lystate contained YY1 protein.

To identify the nucleotides critical for DNA-protein complex formation, we individually mutated sites 1 and 2 within our 37bp probe. We found that mutating either site altered stochiometry of the three complexes. However, none of the bands were lost. Mutation of site 1 enhanced the intensity of the lowest band (complex A), while the faint higher band became hyper-intense following mutation of site 2 (complex C). These results suggest either the binding of the proteins that constitute complex C is enhanced by the disruption of a specific sequence within the probe (i.e. site 2), or binding is mutually exclusive and factors compete for DNA access. Such an observation supports the notion that multiple proteins are cooperatively (perhaps acting synergistically) and/or antagonistically binding the probe. As a gel shift was only observed when the individual 20bp fragments that failed to bind were combined, it is more likely that multiple factors bind cooperatively rather than antagonistically. Thus, each complex represents the averaged migrational properties of a specific combination of proteins.

Bioinformatic analysis of the 37bp fragment identified two putative YY1 transcription factor consensus binding sites (Flanagan et al., 1992; Ye et al., 1994; Yarden & Sliwkoski, 2001) overlapping sites 1 and 2. In order to assess the affinity of RT4 nuclear extract proteins for the YY1 consensus binding site, a competition assay was performed. A control probe containing a previously published YY1 consensus site was labeled and incubated with RT4 nuclear extract and a strong band was noted that was specific and could be ablated by the addition of cold YY1 probe (data not shown). When this non-radiolabeled YY1 control probe was co-incubated with a radiolabeled 37bp fragment and RT4 nuclear extract, complexes A–C were significantly reduced in intensity (Fig. 8D, lane 5) suggesting specific competition. As YY1 and Serum Response Factor (SRF) are known to be able to compete for similar binding sites (Lee et al., 1992; Flanagan et al., 1992; Ye et al., 1994; Yarden & Sliwkoski, 2001), we used an unlabeled SRF probe to test whether SRF bound the 37bp probe. However, co-incubated cold SRF had no significant effect on complex formation (Fig. 8D, lane 6). These results suggest proteins that participate in the formation of complexes A–C also bind the YY1 control probe, but not the SRF control probe.

To directly test the ability of YY1 to bind the 37bp probe, rabbit reticulocyte lysate was used to generate pure recombinant YY1 protein, both with and without a 3′ prime poly-histone tag. The identity of the recombinant YY1 was confirmed by Western blot (Fig. 8E). When co-incubated with labeled 37bp probe, a prominent band was generated, demonstrating that YY1 protein directly binds this sequence of the 3.9kbperi promoter. Given YY1’s nearly ubiquitous expression, this data support the notion that YY1 participates in a complex of proteins driving 3.9kbperi expression patterns.

In Vivo Site Directed Mutagenesis Transgenic Analysis

Having identified evolutionarily conserved YY1 cis-elements in the isolated 37bp element present within the transcriptionally active Peri304 fragment, we set out to determine if the 37bp were specifically necessary for any part of the observed 3.9kbperi-lacZ expression. We therefore deleted the 37bp from the 3.9kbperi-lacZ construct and used it to generate F0 transgenic litters (designated 3900−37bp). Our analysis revealed that deletion of the 37bp site ablated all in vivo lacZ reporter expression (n=5/5; Fig. 9). This result demonstrates that the 37bp site is a necessary enhancer element required for 3.9kbperi expression in the PNS and distal OFT cardiac cushions and that this sequence contains binding sites for YY1, implicating it as a regulator of periostin expression in the Schwann cell and cardiac OFT endocardial cushion cell lineages.

Figure 9. Transgenic Fo analysis of periostin 37bp enhancer requirement.

Figure 9

(A) PCR screening results of Hsp68-3900−37bp F0 transient transgenic embryos that each contain the 3.9kbperi promoter minus the YY1-binding 37bp fragment. Five embryos (#s10, 11, 1, 14, 13 placed in copy # order) were obtained, each of which carried the endogenous periostin promoter (identified as 113 & 219bp PCR fragments following internal SacII diagnostic digestion) as well as the Hsp68-3900−37bp-containing transgenic promoter (identified as a separate 182bp fragment, upper panel). Note that the intensity of the transgene (182bp band) varies, whilst the endogenous bands are invariant. Although all five contained the lacZ transgene (verified via subsequent lacZ-specific PCR screening, lower panel), no β-galactosidase positive cells could be detected (even after a weeks X-gal staining at 37°C). Non-transgenic littermates were used as negative controls. (B & C) E12.5 whole embryo and isolated Hsp68-3900−37bp heart (#10 has highest transgene copy #) stained for lacZ reporter activity. Note the lack of lacZ reporter activity when the 37bp internal enhancer is deleted within the context of the 3.9kbperi promoter (3900−37bp; n=5). Thus, deletion of an internal 37bp upstream region in the 3.9kbperi promoter completely abolishes lacZ reporter activity throughout the entire embryo.

Discussion

Periostin is normally expressed in a wide spectrum of embryonic and adult mouse tissues (Kruzynska-Frejtag et al., 2001; Lindsley et al., 2005) and yet our results demonstrate the cis-elements which control the vast majority of endogenous periostin expression do not reside within the immediate 5′ upstream 3.9kbperi sequence. Instead, we found only a subset of periostin expression domains are regulated by this ~4kb proximal region, suggesting the existence of additional undiscovered regulatory elements elsewhere. Bioinformatic analysis supports this contention by revealing several additional peaks of identity 3′ of 3.9kbperi, including intronic regions (data not shown). While these other homology peaks may harbor important regulatory elements, caution must be exercised in attempting to predict which regions are independently capable of driving transcription based solely on sequence identity. Evaluation of transcriptional activity using cell-culture based functional assays can produce misleading data and requires verification by in vivo experimentation. Thus, generation of transgenic reporter mouse lines remains the gold-standard for assessing the transcriptional activity of putative enhancer and/or repressor elements. Our dissection of 3.9kbperi-lacZ stands as a case in point. For instance, our in vitro studies proved reliably predicative for isolating the Schwann cell enhancer module, but there was no reason to predict the co-capture of the OFT endocardial cushion enhancer. Similarly, Oshima et al. 2002 described a putative Twist site (E-box) located 468bp upstream of the periostin transcription start that is capable of driving reporter expression in vitro in mouse MC3T3-E1 osteoblast cells. Interestingly, we also detect Twist-dependent transactivation in tissue culture when using various mouse mammary tumor cell lines (ABF and SJC, unpublished data). Despite the presence of this conserved E-box in our 3.9kbperi-lacZ reporter mice, we were unable to detect lacZ expression in either the periostium or cranial suture structures in vivo. While this identified Twist site may require additional up or downstream elements to function in vivo, the 3.9kbperi-lacZ data suggests that it is unlikely to be involved in in vivo Schwann cell and distal OFT cushion regulation.

Even more striking is the finding of a regulatory element(s) within the 3.9kbperi that are active in both cardiac OFT and Schwann cells, two such seemingly disparate and highly specific cell populations. This raises questions about possible links between the transcriptional profiles of these two developmentally distinct cell types. Interestingly, Schwann cells and truncal OFT mesenchymal cardiac cushion cells both derive from neural crest cell precursors which have undergone EMT and have migrated to new anatomical locations and express YY1. Significantly, both YY1 and periostin are both amongst a group of 100 genes identified as being upregulated in the solid tumors (Pilarsky et al., 2004). Given periostin’s upregulation in numerous neoplasias and its association with tumor metastasis, transcriptional activation of periostin via the identified PNS/cardiac-OFT enhancer could be driven by transcription factors that promote cell motility or migration. This idea is consistent with periostin’s suggested function as a homophilic adhesion molecule and marker of post-EMT mesenchymal maturation.

Schwann cells and cardiac cushion mesenchyme are also linked by their dependence on the neuregulin-ErbB signaling pathway. Targeted deletions of neuregulin-1 (glial growth factor), ErbB2, and ErbB3 all result in early embryonic lethality secondary to cardiac malformation while also ablating the vast majority of developing Schwann cells (Erickson et al., 1997; Camenisch et al., 2002). Schwann cells and cardiac cushion mesenchyme also occupy tissue niches with similar ECM compositions. Hyaluronan, a major component of the cardiac cushion and myelin sheath ECM, is capable of activating ErbB3 in AV canal explants. Furthermore, AV explants from hyaluronan synthase-2 (Has2) knockout mice, which typically fail to form cushion mesenchyme, are rescued by the pharmacological activation of ErbB2 and ErbB3 (Eggli et al., 1992; Spicer et al., 2004). Unfortunately, Has2 knockout embryos die too early (E9.0) to assess if they suffer from Schwann cell developmental defects, but a proposed Has2-conditional knockout mouse (Spicer et al., 2004) has the potential to address the role of hyaluronan in Schwann cell development in the near future.

In addition, Schwann and endocardial cushion cells share a number of molecular markers. Just as Schwann cells express the EF-hand containing protein S-100, so too do cardiac fibroblast-like cells, which are densely distributed throughout the cardiac skeleton, within the four cardiac valves and in the cardiac chordae tendoneae (Masani et al., 1986). Similarly, Oki et al. 1995 demonstrated that several glial and Schwann cell markers in addition to S-100 (glial fibrillary acidic protein and neurofilament protein) are distributed along the subendocardial site of developing cardiac valves. Finally, the Schwann cell marker Sox10 (as well as Sox 8 and 9) are co-expressed at the sites of endogenous periostin localization within the developing heart valves and autonomic nerves of the embryonic heart (Montero et al., 2002). The fact that Schwann cells and endocardial cushion cells express similar combinations of proteins, including transcription factors, suggests that their transcriptional programs overlap, even if their ultimate phenotypes diverge.

Advances in our understanding of eukaryotic gene transcription have illuminated how combinations of transcription factors act in concert to trans-activate or trans-repress gene expression and help to explain how ‘ubiquitous’ transcription factors can modulate lineage/tissue-specific gene programs (Novina & Roy, 1996; Veitia, 2003). Existing as an enigmatic lynchpin, YY1 is known to be both a transcriptional repressor and/or activator and has been show to physically interact with more than a dozen proteins; including p300, CREB, Hdac2, E1A, FKBP25, C/EBP, c-myc, B23, and Stat5 (Shia et al., 1997; Bergad et al., 2000; Inouye & Seto, 1994; Shrivastava & Calame, 1994) that may cooperatively result in tissue restricted transcriptional regulation. YY1 is essential for embryonic life with its loss leading to peri-implantation lethality (Donohoe et al., 1999). Hundreds of genes may be directly and indirectly regulated by YY1, although the exact mechanism through which the factor acts remains unclear in many cases (Inouye & Seto, 1994; Donohoe et al., 1999). Recent data suggested that YY1 might induce chromatin remodeling in target genes through the recruitment of histone-modifying enzymes (Thomas & Seto, 1999). Furthermore, the manipulation of YY1 gene dosage has also been shown to profoundly alter global gene expression in the developing embryo (Affar et al., 2006). With specific regard to the developing cardiac valves, supportive data are starting to emerge that show SMAD-mediated modulation of YY1 activity can regulate BMP responses and cardiac-specific expression of a GATA4/5/6-dependent Nkx2.5 enhancer (Lee et al., 2004). Thus, YY1 could be acting as a novel SMAD-interacting protein that represses SMAD transcriptional activities in a gene-specific manner and therefore regulates cell differentiation induced by TGFβ superfamily pathways (Kurisaki et al., 2003).

This study has defined a novel Schwann cell and distal OFT cushion-specific enhancer that links the transcriptional programs of these two divergent lineages, and has improved our understanding of the likely upstream mechanisms that regulate expression. Understanding how periostin’s spatiotemporal expression pattern is driven is the first step to facilitating the development of experimental tools essential for studying the role of periostin in pathological disorders such as neuromas, nerve tumors and cardiac valve malformations. Additionally, the 3.9kbperi promoter can be utilized to drive tissue-specific expression of Cre recombinase in transgenic mice, and given the current lack of any cardiac endocardial cushion-restricted promoters (never mind one that will enable the molecular characterization of inlet verses outflow cushion morphogenesis) this may be a useful molecular reagent. Our analysis has provided potential links between precursor Schwann cells and OFT endocardial cushion lineages and also implicated the YY1 protein in post-migratory neural crest differentiation events. Finally, uncovering the additional trans-factors and cis-elements that regulate periostin’s expression in these and other tissues is the subject of ongoing investigations, the results of which will provide greater insights into the mechanisms by which the tissues of the developing mammalian embryo so precisely determine their cell identity and fate.

Acknowledgments

Special thanks to Drs. Joe Bidwell and Simon Rhodes for their helpful advice. These studies were supported, in part, by an American Heart Association Midwest Predoctoral Fellowship to AL, National Institutes of Health Training in Vascular Biology and Medicine T32 HL079995 postdoctoral support for PS, Riley Children’s Foundation support for HZ, and HL60714 grant and IU Department of Pediatrics/Cardiology support for SJC.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  1. Affar EB, Gay F, Shi Y, Liu H, Huarte M, Wu S, Collins T, Li E, Shi Y. Essential Dosage-Dependent Functions of the Transcription Factor Yin Yang 1 in Late Embryonic Development and Cell Cycle Progression. Mol Cell Biol. 2006;26:3565–3581. doi: 10.1128/MCB.26.9.3565-3581.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armstrong EJ, Bischoff J. Heart Valve Development: Endothelial Cell Signaling and Differentiation. Circ Res. 2004;95:459–470. doi: 10.1161/01.RES.0000141146.95728.da. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson R, Rich J, Wang X. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004;5:329–339. doi: 10.1016/s1535-6108(04)00081-9. [DOI] [PubMed] [Google Scholar]
  4. Barnett JV, Desgrosellier JS. Early events in valvulogenesis: A signaling perspective. Birth Defects Research Part C: Embryo Today: Reviews. 2003;69:58–72. doi: 10.1002/bdrc.10006. [DOI] [PubMed] [Google Scholar]
  5. Bergad PL, Towle HC, Berry SA. Yin-yang 1 and Glucocorticoid Receptor Participate in the Stat5-mediated Growth Hormone Response of the Serine Protease Inhibitor 2.1 Gene. J Biol Chem. 2000;275:8114–8120. doi: 10.1074/jbc.275.11.8114. [DOI] [PubMed] [Google Scholar]
  6. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave K-A, Birchmeier C, Wegner M. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 2001;15:66–78. doi: 10.1101/gad.186601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med. 2002;8:850–855. doi: 10.1038/nm742. [DOI] [PubMed] [Google Scholar]
  8. Conway SJ, Bundy J, Chen J, Dickman E, Rogers R, Will BM. Abnormal neural crest stem cell expansion is responsible for the conotruncal heart defects within the Splotch (Sp2H) mouse mutant. Cardiovascular Res. 2000;47:314–328. doi: 10.1016/s0008-6363(00)00098-5. [DOI] [PubMed] [Google Scholar]
  9. Conway SJ, Kruzynska-Frejtag A, Kneer PL, Machnicki M, Koushik SV. What cardiovascular defect does my prenatal mouse mutant have, and why? Genesis. 2003;35:1–21. doi: 10.1002/gene.10152. [DOI] [PubMed] [Google Scholar]
  10. Delot E. Control of endocardial cushion and cardiac valve maturation by BMP signaling pathways. Mol Genet Metab. 2003;80:27–35. doi: 10.1016/j.ymgme.2003.07.004. [DOI] [PubMed] [Google Scholar]
  11. Dignam J, Martin P, Shastry B, Roeder R. Eukaryotic gene transcription with purified components. Methods Enzymol. 1983;101:582–98. doi: 10.1016/0076-6879(83)01039-3. [DOI] [PubMed] [Google Scholar]
  12. Donohoe ME, Zhang X, McGinnis L, Biggers J, Li E, Shi Y. Targeted Disruption of Mouse Yin Yang 1 Transcription Factor Results in Peri-Implantation Lethality. Mol Cell Biol. 1999;19:7237–7244. doi: 10.1128/mcb.19.10.7237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Eggli PS, Lucocq J, Ott P, Graber W, Zypen Evd. Ultrastructural localization of hyaluronan in myelin sheaths of the rat central and rat and human peripheral nervous systems using hyaluronan-binding protein-gold and link protein-gold. Neuroscience. 1992;48:737–44. doi: 10.1016/0306-4522(92)90417-z. [DOI] [PubMed] [Google Scholar]
  14. Erickson SL, O’Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M, Lu LH, Moore MW. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997;124:4999–5011. doi: 10.1242/dev.124.24.4999. [DOI] [PubMed] [Google Scholar]
  15. Firulli ABOE. Modular regulation of muscle gene transcription: a mechanism for muscle cell diversity. Trends Genet. 1997;13:364–9. doi: 10.1016/s0168-9525(97)01171-2. [DOI] [PubMed] [Google Scholar]
  16. Flanagan JR, Becker KG, Ennist DL, Gleason SL, Driggers PH, Levi BZ, Appella E, Ozato K. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. MCB. 1992;12:38–44. doi: 10.1128/mcb.12.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin Secreted by Epithelial Ovarian Carcinoma Is a Ligand for {alpha}V{beta}3 and {alpha}V{beta}5 Integrins and Promotes Cell Motility. Cancer Res. 2002;62:5358–5364. [PubMed] [Google Scholar]
  18. Gonzalez H, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring P, Mitsudo K, Kim H, Clayman G. Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:754–9. doi: 10.1001/archotol.129.7.754. [DOI] [PubMed] [Google Scholar]
  19. Gonzalez-Martinez T, Perez-Piñera P, Díaz-Esnal B, Vega JA. S100 proteins in the human peripheral nervous system. Microscopy Research and Technique. 2003;60:633–638. doi: 10.1002/jemt.10304. [DOI] [PubMed] [Google Scholar]
  20. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2005;25:1125–1142. doi: 10.1038/sj.onc.1209080. [DOI] [PubMed] [Google Scholar]
  21. Gronroos E, Terentiev AA, Punga T, Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. PNAS. 2004;101:12165–12170. doi: 10.1073/pnas.0402283101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hai M, Bidichandani SI, Patel PI. Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene. Journal of Neuroscience Research. 2001;65:508–519. doi: 10.1002/jnr.1181. [DOI] [PubMed] [Google Scholar]
  23. Hai M, Muja N, DeVries GH, Quarles RH, Patel PI. Comparative analysis of Schwann cell lines as model systems for myelin gene transcription studies. Journal of Neuroscience Research. 2002;69:497–508. doi: 10.1002/jnr.10327. [DOI] [PubMed] [Google Scholar]
  24. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald L, Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14:1239–49. doi: 10.1359/jbmr.1999.14.7.1239. [DOI] [PubMed] [Google Scholar]
  25. Hunt D, Hossain-Ibrahim K, Mason MR, Coffin RS, Lieberman AR, Winterbottom J, Anderson PN. ATF3 upregulation in glia during Wallerian degeneration: differential expression in peripheral nerves and CNS white matter. BMC Neurosci. 2004;5:9. doi: 10.1186/1471-2202-5-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Inouye CJ, Seto E. Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23. J Biol Chem. 1994;269:6506–6510. [PubMed] [Google Scholar]
  27. Jessen KR, Mirsky R. Signals that determine Schwann cell identity. Journal of Anatomy. 2002;200:367–376. doi: 10.1046/j.1469-7580.2002.00046.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci. 2005;6:671–682. doi: 10.1038/nrn1746. [DOI] [PubMed] [Google Scholar]
  29. Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. Fate of the mammalian cardiac neural crest. Development. 2000;127:1607–16. doi: 10.1242/dev.127.8.1607. [DOI] [PubMed] [Google Scholar]
  30. Ji X, Chen D, Xu C, Harris S, Mundy G, Yoneda T. Patterns of gene expression associated with BMP-2-induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A. J Bone Miner Res. 2000;18:132–9. doi: 10.1007/s007740050103. [DOI] [PubMed] [Google Scholar]
  31. Kawamoto T, Noshiro M, Shen M, Nakamasu K, Hashimoto K, Kawashima-Ohya Y, Gotoh O, Kato Y. Structural and phylogenetic analyses of RGD-CAP/[beta]ig-h3, a fasciclin-like adhesion protein expressed in chick chondrocytes. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1998;1395:288–292. doi: 10.1016/s0167-4781(97)00172-3. [DOI] [PubMed] [Google Scholar]
  32. Kii I, Amizuka N, Minqi L, Kitajima S, Saga Y, Kudo A. Periostin is an extracellular matrix protein required for eruption of incisors in mice. Biochem Biophys Res Commun. 2006;342:766–72. doi: 10.1016/j.bbrc.2006.02.016. [DOI] [PubMed] [Google Scholar]
  33. Kothary R, Clapoff S, Darling S, Perry M, Moran L, Rossant J. Inducible expression of an hsp68-lacZ hybrid gene in transgenic mice. Development. 1989;105:707–14. doi: 10.1242/dev.105.4.707. [DOI] [PubMed] [Google Scholar]
  34. Kruzynska-Frejtag A, Machnicki M, Rogers R, Markwald RSJC. Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation. Mech Dev. 2001;103:183–8. doi: 10.1016/s0925-4773(01)00356-2. [DOI] [PubMed] [Google Scholar]
  35. Kruzynska-Frejtag A, Wang J, Maeda M, Rogers R, Krug E, Hoffman S, Markwald RR, Conway SJ. Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction. Developmental Dynamics. 2004;229:857–868. doi: 10.1002/dvdy.10453. [DOI] [PubMed] [Google Scholar]
  36. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M, Takata T. Periostin Promotes Invasion and Anchorage-Independent Growth in the Metastatic Process of Head and Neck Cancer. Cancer Res. 2006;66:6928–6935. doi: 10.1158/0008-5472.CAN-05-4540. [DOI] [PubMed] [Google Scholar]
  37. Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I, Wegner M. Sox10, a Novel Transcriptional Modulator in Glial Cells. J Neurosci. 1998;18:237–250. doi: 10.1523/JNEUROSCI.18-01-00237.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kurisaki K, Kurisaki A, Valcourt U, Terentiev AA, Pardali K, ten Dijke P, Heldin C-H, Ericsson J, Moustakas A. Nuclear Factor YY1 Inhibits Transforming Growth Factor {beta}-and Bone Morphogenetic Protein-Induced Cell Differentiation. Mol Cell Biol. 2003;23:4494–4510. doi: 10.1128/MCB.23.13.4494-4510.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Le Douarin NM, Dulac C, Dupin E, Cameron-Curry P. Glial cell lineages in the neural crest. Glia. 1991;4:175–184. doi: 10.1002/glia.440040209. [DOI] [PubMed] [Google Scholar]
  40. Lee K-H, Evans S, Ruan TY, Lassar AB. SMAD-mediated modulation of YY1 activity regulates the BMP response and cardiac-specific expression of a GATA4/5/6-dependent chick Nkx2.5 enhancer. Development. 2004;131:4709–4723. doi: 10.1242/dev.01344. [DOI] [PubMed] [Google Scholar]
  41. Lee TC, Shi Y, Schwartz RJ. Displacement of BrdUrd-induced YY1 by serum response factor activates skeletal alpha-actin transcription in embryonic myoblasts. PNAS. 1992;89:9814–8. doi: 10.1073/pnas.89.20.9814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Li G, Oparil S, Sanders J, Zhang L, Dai M, Chen L, Conway S, McNamara C, Sarembock I. Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis. 2005;188:292–300. doi: 10.1016/j.atherosclerosis.2005.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Lindsley A, Li W, Wang J, Maeda N, Rogers R, Conway SJ. Comparison of the four mouse fasciclin-containing genes expression patterns during valvuloseptal morphogenesis. Gene Expression Patterns. 2005;5:593–600. doi: 10.1016/j.modgep.2005.03.005. [DOI] [PubMed] [Google Scholar]
  44. Litvin J, Selim A-H, Montgomery MO, Lehmann K, Rico MC, Devlin H, Bednarik DP, Safadi FF. Expression and function of periostin-isoforms in bone. Journal of Cellular Biochemistry. 2004;92:1044–1061. doi: 10.1002/jcb.20115. [DOI] [PubMed] [Google Scholar]
  45. Litvin J, Zhu S, Norris R, Markwald R. Periostin family of proteins: Therapeutic targets for heart disease. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology. 2005;287A:1205–1212. doi: 10.1002/ar.a.20237. [DOI] [PubMed] [Google Scholar]
  46. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucl Acids Res. 2004;32:W217–221. doi: 10.1093/nar/gkh383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Madison D, Kruger W, Kim T, Pfeiffer S. Differential expression of rab3 isoforms in oligodendrocytes and astrocytes. J Neurosci Res. 1996;45:258–68. doi: 10.1002/(SICI)1097-4547(19960801)45:3<258::AID-JNR7>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  48. Masani F, Iwanaga T, Shibata A, Fujita T. Immunohistochemical demonstration of S-100 protein in fibroblast-like cells of the guinea-pig heart. Arch Histol Jpn. 1986;49:117–27. doi: 10.1679/aohc.49.117. [DOI] [PubMed] [Google Scholar]
  49. McAllister L, Goodman C, Zinn K. Dynamic expression of the cell adhesion molecule fasciclin I during embryonic development in Drosophila. Development. 1992;115:267–76. doi: 10.1242/dev.115.1.267. [DOI] [PubMed] [Google Scholar]
  50. McFadden DG, Charite J, Richardson JA, Srivastava D, Firulli AB, Olson EN. A GATA-dependent right ventricular enhancer controls dHAND transcription in the developing heart. Development. 2000;127:5331–5341. doi: 10.1242/dev.127.24.5331. [DOI] [PubMed] [Google Scholar]
  51. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386–390. doi: 10.1038/378386a0. [DOI] [PubMed] [Google Scholar]
  52. Miskimins R, Miskimins W. A role for an AP-1-like site in the expression of the myelin basic protein gene during differentiation. Int J Dev Neurosci. 2001;19:85–91. doi: 10.1016/s0736-5748(00)00066-6. [DOI] [PubMed] [Google Scholar]
  53. Montero J, Giron B, Arrechedera H, Cheng Y, Scotting P, Chimal-Monroy J, Garcia-Porrero J, Hurle J. Expression of Sox8, Sox9 and Sox10 in the developing valves and autonomic nerves of the embryonic heart. Mech Dev. 2002;118:199–202. doi: 10.1016/s0925-4773(02)00249-6. [DOI] [PubMed] [Google Scholar]
  54. Norris R, Damon B, Mironov V, Kasyanov V, Ramamurthi A, Moreno-Rodriguez R, Trusk T, Potts JD, Goodwin RL, Davis J, Hoffman S, Wen X, Sugi Y, Kern CB, Mjaatvedt CH, Turner DK, Oka T, Conway SJ, Molkentin JD, Forgacs G, Markwald RR. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem. 2007 doi: 10.1002/jcb.21224. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Novina C, Roy A. Core promoters and transcriptional control. Trends Genet. 1996;12:351–5. [PubMed] [Google Scholar]
  56. Oki T, Fukuda N, Kawano T, Iuchi A, Tabata T, Manabe K, Kageji Y, Sasaki M, Yamada H, Ito S. Histopathologic studies of innervation of normal and prolapsed human mitral valves. J Heart Valve Dis. 1995;4:496–502. [PubMed] [Google Scholar]
  57. Oshima A, Tanabe H, Yan T, Lowe G, Glackin C, Kudo A. A novel mechanism for the regulation of osteoblast differentiation: transcription of periostin, a member of the fasciclin I family, is regulated by the bHLH transcription factor, twist. J Cell Biochem. 2002;86:792–804. doi: 10.1002/jcb.10272. [DOI] [PubMed] [Google Scholar]
  58. Ovcharenko I, Loots GG, Hardison RC, Miller W, Stubbs L. zPicture: Dynamic Alignment and Visualization Tool for Analyzing Conservation Profiles. Genome Res. 2004;14:472–477. doi: 10.1101/gr.2129504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6:744–50. doi: 10.1593/neo.04277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Rios H, Koushik SV, Wang H, Wang J, Zhou H-M, Lindsley A, Rogers R, Chen Z, Maeda M, Kruzynska-Frejtag A, Feng JQ, Conway SJ. periostin Null Mice Exhibit Dwarfism, Incisor Enamel Defects, and an Early-Onset Periodontal Disease-Like Phenotype. Mol Cell Biol. 2005;25:11131–11144. doi: 10.1128/MCB.25.24.11131-11144.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fuji Y. Expression of the periostin mRNA level in neuroblastoma. Journal of Pediatric Surgery. 2002;37:1293–1297. doi: 10.1053/jpsu.2002.34985. [DOI] [PubMed] [Google Scholar]
  62. Sasaki H, Yu C-Y, Meiru Dai CT, Loda M, Auclair D, Chen LB, Elias A. Elevated Serum Periostin Levels in Patients with Bone Metastases from Breast but not Lung Cancer. Breast Cancer Research and Treatment. 2004;77:245–252. doi: 10.1023/a:1021899904332. [DOI] [PubMed] [Google Scholar]
  63. Schepers GE, Bullejos M, Hosking BM, Koopman P. Cloning and characterisation of the Sry-related transcription factor gene Sox8. Nucl Acids Res. 2000;28:1473–1480. doi: 10.1093/nar/28.6.1473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Shia Y, Leeb J-S, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1997;1332:F49–F66. doi: 10.1016/s0304-419x(96)00044-3. [DOI] [PubMed] [Google Scholar]
  65. Shrivastava A, Calame K. An analysis of genes regulated by the multi-functional transcriptional regulator Yin Yang-1. Nucleic Acid Res. 1994;22:5151–5. doi: 10.1093/nar/22.24.5151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Shrivastava A, Saleque S, Kalpana G, Artandi S, Goff G, Calame K. Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc. Science. 1993;262:1889–92. doi: 10.1126/science.8266081. [DOI] [PubMed] [Google Scholar]
  67. Spicer AP, Tien JL, Joo A, RAB Investigation of hyaluronan function in the mouse through targeted mutagenesis. Glycoconjugate Journal. 2004;19:341–345. doi: 10.1023/A:1025321105691. [DOI] [PubMed] [Google Scholar]
  68. Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, Zheng Q, Protter AA, Schreiner GF, White RT. Altered Patterns of Gene Expression in Response to Myocardial Infarction. Circ Res. 2000;86:939–945. doi: 10.1161/01.res.86.9.939. [DOI] [PubMed] [Google Scholar]
  69. Sun Y, Liang X, Najafi N, Cass M, Lin L, Cai C, Chen J, Evans S. Islet 1 is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells. Dev Biol. 2006 doi: 10.1016/j.ydbio.2006.12.048. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie A, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104. doi: 10.1016/j.jaci.2006.02.046. [DOI] [PubMed] [Google Scholar]
  71. Takeshita SKR, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294:271–8. doi: 10.1042/bj2940271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Thomas M, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene. 1999;236:197–208. doi: 10.1016/s0378-1119(99)00261-9. [DOI] [PubMed] [Google Scholar]
  73. Thompson J, Higgins D, Gibson T. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acid Res. 1994;22:4673–80. doi: 10.1093/nar/22.22.4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Toda K, Small JA, Goda S, Quarles RH. Biochemical and Cellular Properties of Three Immortalized Schwann Cell Lines Expressing Different Levels of the Myelin-Associated Glycoprotein. Journal of Neurochemistry. 1994;63:1646–1657. doi: 10.1046/j.1471-4159.1994.63051646.x. [DOI] [PubMed] [Google Scholar]
  75. Veitia R. A sigmoidal transcriptional response: cooperativity, synergy and dosage effects. Biological reviews of the Cambridge Philosophical Society. 2003;78:149–170. doi: 10.1017/s1464793102006036. [DOI] [PubMed] [Google Scholar]
  76. Wang C-C, Chen JJW, Yang P-C. Multifunctional transcription factor YY1: a therapeutic target in human cancer? Expert Opinion on Therapeutic Targets. 2006;10:253–266. doi: 10.1517/14728222.10.2.253. [DOI] [PubMed] [Google Scholar]
  77. Wegner M. Transcriptional control in myelinating glia: flavors and spices. Glia. 2000;31:1–14. doi: 10.1002/(sici)1098-1136(200007)31:1<1::aid-glia10>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  78. Yang W-M, Yao Y-L, Seto E. The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor YY1. EMBO. 2001;20:4814–4825. doi: 10.1093/emboj/20.17.4814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–39. doi: 10.1016/j.cell.2004.06.006. [DOI] [PubMed] [Google Scholar]
  80. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37. doi: 10.1038/35052073. [DOI] [PubMed] [Google Scholar]
  81. Ye J, Cippitelli M, Dorman L, Ortaldo JR, Young HA. The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. MCB. 1996;16:4744–4753. doi: 10.1128/mcb.16.9.4744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Ye J, Young HA, Ortaldo JR, Ghosh P. Identification of a DNA binding site for the nuclear factor YY1 in the human GM-CSF core promoter. Nucleic Acid Res. 1994;22:5672–5678. doi: 10.1093/nar/22.25.5672. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES